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ABSTRACT: Parenteral nutrition is used to treat children that cannot be fully fed by the enteral route. While the revised ESPGHAN/
ESPEN/ESPR/CSPEN pediatric parenteral nutrition guidelines provide clear guidance on the use of parenteral nutrition in neonates,
infants, and children based on current available evidence, they have helped to crystallize areas where research is lacking or more
studies are needed in order to refine recommendations. This paper collates and discusses the research gaps identified by the
authors of each section of the guidelines and considers each nutrient or group of nutrients in turn, together with aspects around
delivery and organization. The 99 research priorities identified were then ranked in order of importance by clinicians and
researchers working in the field using a survey methodology. The highest ranked priority was the need to understand the
relationship between total energy intake, rapid catch-up growth, later metabolic function, and neurocognitive outcomes. Research
into the optimal intakes of macronutrients needed in order to achieve optimal outcomes also featured prominently. Identifying
research priorities in PN should enable research to be focussed on addressing key issues. Multicentre trials, better definition of
exposure and outcome variables, and long-term metabolic and developmental follow-up will be key to achieving this.
Pediatric Research; https://doi.org/10.1038/s41390-021-01670-9
IMPACT:
● The recent ESPGHAN/ESPEN/ESPR/CSPEN guidelines for pediatric parenteral nutrition provided updated guidance for providing
parenteral nutrition to infants and children, including recommendations for practice.
● However, in several areas there was a lack of evidence to guide practice, or research questions that remained unanswered. This
paper summarizes the key priorities for research in pediatric parenteral nutrition, and ranks them in order of importance
according to expert opinion.
INTRODUCTION
Parenteral nutrition (PN) is crucial to treat children that cannot
be fully fed by oral or enteral route. The revised European
guidelines on pediatric PN were published in 2018 by the
European Society of Paediatric Gastroenterology, Hepatology
and Nutrition (ESPGHAN), the European Society for Clinical
Nutrition and Metabolism (ESPEN), the European Society of
Paediatric Research (ESPR) together with the Chinese Society of
Parenteral and Enteral Nutrition (CSPEN). These guidelines,
updated from the previous version from 2005 (ref. 1), are a
huge achievement, representing several decades of research
and knowledge accumulation in pediatric PN, summarized into
recommendations for practice based on the available evidence
and consensus opinion to provide up-to-date evidence for
health professionals working with infants, children, and
adolescents receiving PN2.
While much progress has been made in the past two decades in
terms of the evidence base, during the process of guideline
development the multidisciplinary working party of professionals
identified multiple gaps in knowledge where there was a need for
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additional research. Knowing where further studies are needed is
important for improving neonatal and pediatric care.
Defining research priorities may serve as a common rallying point
to focus resources and attract scientists and scholars into collaborative
work around these research goals. In this context, the ESPR Section on
Nutrition, Gastroenterology and Metabolism, on behalf of ESPEN/
ESPEN/ESPR/CSPEN, aimed to summarize research priorities in the
field of pediatric PN based on the knowledge gaps identified during
the generation of the recent guidelines, and highlight those which
seem most important and urgent.
Table 1. Key research priorities for energy and macronutrients in pediatric parenteral nutrition.
Topic (number of respondents) Priorities Number
of votes
Rank
Energy (59) For all children and infants who receive parenteral nutrition, understand the
relationship between total energy intake, rapid catch-up growth and long-term
metabolic function and neurocognitive outcomes
40 1
In critically ill children, define optimal energy intake for different phases of illness
(acute, stable, and recovery) and the optimal route and doses of macro- and
micronutrients
32 2
In preterm infants, define optimal energy:protein ratio for growth and later long-
term metabolic function and neurocognitive outcomes
30 3
For all children and infants who receive parenteral nutrition, establishing more
robust evidence and recommendations for optimal energy intakes during PN
20 4
In critically ill children, defining the energy:protein ratio for optimal body
composition and clinical outcomes
13 5
In children with traumatic brain injury, septic shock, burns, and severe
undernourishment, establish energy requirements in the different phases of disease
13 5
Amino acids (57) For critically ill children who receive parenteral nutrition, understand the
pathophysiological mechanisms underlying the harmful effect of administering
proteins in the acute phase of critical illness (e.g. impaired autophagy)
30 1
In preterm infants, undertaking studies (ideally RCTs) to investigate the impact of
different PN amino acid intakes on growth during PN
28 2
In preterm infants, define the optimal glucose and lipid intakes for maximizing
protein accretion and growth at various parenteral amino acid intakes
25 3
In critically ill term infants and older children, establishing better data to enable
firm conclusions on the advisable lower and upper limits for protein intake, based
on optimizing short- and long-term clinical outcomes
25 3
For critically ill children, define the optimal dose and composition of amino acid
mixture for optimal short- and long-term clinical outcomes
24 5
Lipids (56) In preterm infants, determine the initial, optimal and/or maximal dose of lipid
infusion and the ideal fatty acid (FA) composition needed to achieve the best long-
term effects on morbidity, growth, and neurodevelopment
39 1
For all children who receive parenteral nutrition, understand the effect of the type
and dose of different intravenous lipid emulsions (ILEs) on the reversal of intestinal
failure associated liver disease (IFALD)
28 2
For all children and infants who receive parenteral nutrition, clearly define an
upper limit of lipid intake during sepsis based on optimizing short- and long-term
clinical outcomes
26 3
In preterm infants, develop lipid emulsions containing both DHA and AA at
significant balanced amounts, and test their effectiveness on improving short- and
long-term clinical outcomes
25 4
For all children and infants who receive parenteral nutrition, understanding of the
impact of timing of commencement and dosage of PN lipid on outcomes
15 5
Carbohydrates (56) For preterm infants, establish a robust definition of hyperglycemia, and compare
effectiveness of management using insulin to a reduction carbohydrate for its
impact on mortality, morbidity, growth, and long-term metabolic function and
neurocognitive outcomes
41 1
In critically ill neonates and children, characterize the relationship between
excessive glucose intake and dyslipidemia
24 2
In critically ill infants and children, understand the consequences of hypoglycemia
on long-term outcomes
24 2
For all children and infants who receive parenteral nutrition, establish the potential
benefits of increased glucose intake whilst avoiding hyperglycemia
22 4
For all children and infants who receive parenteral nutrition, investigate endogenous
glucose production rates in order to inform recommended glucose intakes
17 5
RCT randomized controlled trial, PN parenteral nutrition, NEC necrotizing enterocolitis, FA fatty acids, ILE intravenous lipid emulsion, AA arachidonic acid, DHA
docosahexaenoic acid, IFALD intestinal failure associated liver disease.















Table 2. Key research priorities for fluid, electrolytes, calcium, phosphate, magnesium and micronutrients in pediatric parenteral nutrition.
Topic (number of respondents) Priorities Number
of votes
Rank
Fluids and electrolytes (56) For neonates during the initial postnatal period, define optimal fluid and
electrolyte requirements, including electrolyte to macronutrient ratios
35 1
For neonates with varying gestational age and birth weight, determine the course
of weight loss and gain after birth for optimal outcomes
28 2
For all children and infants who receive parenteral nutrition, understanding the
short-, medium-, and long-term clinical effects of the metabolic acidosis
associated with parenteral nutrition
21 3
In preterm infants, neonates, and children, undertake studies (ideally RCTs) to
determine the short- and long-term effects of fluid therapy with sodium and
chloride concentrations similar to that of plasma for “maintenance hydration”
19 4
During the transition phase after birth in neonates, understand the relationship





For all children and infants who receive parenteral nutrition, explore the optimum
surrogate parameter for monitoring bone mineral accretion.
28 1
For all children and infants who receive parenteral nutrition, develop bedside
tools to individually monitor bone mineral (microcrystalline apatite) accretion and
bone mineral status ((Ca+P)/body weight)
24 2
In preterm infants, understand the metabolic changes that occur on refeeding,
including include target values of calcium, phosphate, and magnesium needed to
stabilize electrolyte balances and improve bone mineralization considering
nutritional intake and gestational age
22 3
For all children and infants who receive parenteral nutrition, generate more
evidence to enable robust recommendations for phosphate requirements based
on calcium deposition and protein accretion in the same way as can be done for
adults.
18 4
In newborn infants, understand the minimum bone mineral accretion to achieve
within the first 2–4 weeks of life
17 5
Iron and trace elements (56) In children of in different age groups and different stress status who receive PN,
define normal ranges for biomarkers of iron and trace element status
36 1
In infants and children on long-term PN, identify how minimal enteral nutrition
may meet needs for trace elements including copper, chromium, manganese,
molybdenum, and selenium.
32 2
For children on PN in different populations (very preterm infants, children below 2
years of age, term infants with gastrointestinal failure or infants with IFALD, older
children, etc.), determine the safety, efficacy, and stability of different iron
compounds
22 3
Assess the compatibility/stability of available iron and trace element compounds
in various PN solutions
19 4
For all children and infants who receive PN, evaluate trace element contamination
in PN products, e.g. manganese and chromium.
9 5
Fat soluble vitamins (56) In preterm infants, determine the vitamin D content for PN for optimal short- and
long-term outcomes
28 1
For all children and infants who receive PN, understand the health effects of
additional vitamin D supplementation (in addition to its role in calcium and
phosphate metabolism), such as prevention of immune-related and infectious
diseases, cardiovascular disease, and cancer.
20 2
In preterm and VLBW infants, establish what constitutes an adequate supply and
plasma concentration of vitamin A with regard to optimal short- and long-term
clinical outcomes
19 3
In both infants receiving oral vitamin K supplementation and those whose
mothers have taken medications that interfere with vitamin K metabolism, define
optimal dose of parenteral vitamin K to ensure sufficiency
16 4
For all children and infants who receive PN, compare the delivery of vitamin A in
an intravenous emulsion compared with repeated intramuscular injection in
terms of the benefits on vitamin A status, safety, and acceptability
15 5
For all children and infants who receive PN, establish the upper and lower limits
for the dose of vitamin E needed for optimal outcomes
15 5
Water soluble vitamins (56) For all children and infants who receive PN, explore the precise requirement of B
vitamins (thiamine, riboflavin, pyridoxine, cobalamin, niacin, pantothenic acid,
biotin)
35 1




The revised ESPGHAN/ESPR/ESPEN/CSPEN pediatric PN guidelines
consist of separate papers for energy, individual macro- and
micronutrient needs, fluid requirements, venous access, organiza-
tional aspects, home PN, standardized vs. individualized PN, and
safety considerations for prevention and management of compli-
cations. For each paper, the lead author or their delegate was
asked to summarize current gaps in knowledge that became
apparent while compiling the revised guidance, and by liaising
with co-authors. Research agendas were proposed that would help
address key issues on that topic, together with some brief, relevant
background information and/or justification for the research
priorities identified. Two authors (M.J. and M.S.P.) then collated
all the responses into a list of all research priorities identified (see
Supplementary file 1), which was circulated to all lead authors of
the original guidance for comment before being finalized.
Next, given that the original 2018 PN guideline authors
identified multiple research gaps, we aimed to rank them in
order of importance. An electronic survey was then performed
through the online tool Limesurvey v 3.2 (LimeSurvey GmbH
Survey Services and Consulting, Hamburg, Germany) between
April 2020 and May 2020. A unique link to the questionnaire was
sent to the 47 members of the ESPGHAN/ESPEN/ESPR/CSPEN
Working Group on Pediatric Parenteral Nutrition (who were all
involved in drafting the guidelines) and to the 41 members of the
ESPR section on Nutrition, Gastroenterology and Metabolism (11
of whom were involved in the drafting the guidelines, and were
already included as part of the ESPGHAN/ESPEN/ESPR/CSPEN
group). All participants were therefore healthcare professionals
with extensive experience in pedaitric nutrition and/or in
managing PN from a wide range of European countries, Israel,
and China. Non-responders received a reminder email after
2 weeks. For each topic area, clinicians and researchers working
in the field were asked to choose a minimum of one and a
maximum of three of the research priorities for each topic, and
research priorities for each topic were then ranked based on the
number of votes. To highlight the main overall priorities,
respondents were asked at the end of the survey to select five
of their previous choices across the survey that they felt were the
most important overall across all the topics. Again, these were
ranked according to the total number of votes for each priority.
RESULTS
The initial process consultation process carried out with the
original ESPGHAN/ESPEN/ESPR/CSPEN guideline authors identified
a total of 99 research priorities, 10 of which focussed specifically
on the preterm infant population. The complete list of research
priorities can be seen in Supplementary File 1. The initial survey
for ranking the priorities was sent to 77 clinicians and researchers
working in the field. Eleven responded to say that they were no
longer working in the field or had a conflict of interest, leaving 66
potential respondents. There were 55 full responses and 4 partial,
making an overall response rate of 89.4%. Thirty-five (59%) of
respondents were male and 24 (41%) female. The resulting top
five ranked priorities for each topic area following voting are
shown in Table 1 (energy and macronutrients), Table 2 (fluid,
electrolytes, calcium, phosphate, magnesium and micronutrients),
and Table 3 (venous access, complications, organizational aspects,
home PN and ready to use and standardized formulations).
Energy
There are still considerable gaps in knowledge regarding how
energy needs differ in both different phases of critical illness
(acute, stable, recovery), chronic illness, and in infants born
preterm (Table 1). Acute injury, infection, or a surgical insult
induce a metabolic response that is proportional to the
magnitude, nature, and duration of the injury. This response is
characterized by a brief hypometabolic phase followed by a
hypermetabolic phase, which is catabolic in nature. The duration
of this catabolic response in most critically ill children is unknown
but might be short. The impact of acute and chronic illness on
energy requirements in children is not well understood3. Recent
work has highlighted the uncertainties around optimal energy
intakes in critically ill children accounting for the endogenous
production of energy in the acute phase of disease, suggesting
that more work is also needed to define these for term and
preterm infants4. In addition, the optimal proportions of energy
delivered by carbohydrate and lipid in PN, and the optimal ratio of
energy to protein remains unclear, particularly for preterm infants.
Amino acids
In preterm infants, defining optimal amino acid intake is
challenging and more evidence is needed regarding the amino
acid intake (and the relative amount of energy) needed for
optimal metabolic and neurodevelopmental outcomes. No studies
exist looking at protein/amino acid intake in relation to
(functional) outcome in critically ill children, though several
studies suggest that nitrogen balance is improved by higher
amino acid intakes. However, a secondary analysis of the PEPaNIC
study reported that a higher total daily amino acid intake during
the first week of pediatric intensive care unit (PICU) stay was
associated with an increased likelihood of acquiring new
infections, and a lower likelihood of both earlier weaning from
mechanical ventilation and early live PICU discharge5. While these
findings need to be interpreted with caution in light of the issues
associated with such secondary analyses, coupled with the
heterogeneous nature of the PEPaNIC study population, intersite
Table 2 continued
Topic (number of respondents) Priorities Number
of votes
Rank
In children and infants who receive PN, understand of the role of folic acid in the
establishment of an individual’s DNA methylation profile during development,
including its involvement in methylation profiles and in turn long-term health,
during the life course
31 2
In preterm infants, investigate the benefits of additional folic acid supplementation
over and above current recommendations, as this is currently is controversial
21 3
For preterm infants, term infants, and older children, define the vitamin C
requirements for optimal short- and long-term clinical outcomes
19 4
In children and infants who receive PN, develop clinical indicators for mild and
moderate vitamin C deficiency
19 4
RCT randomized controlled trial, VLBW very low birth weight, PN parenteral nutrition, VLBW very low birth weight, DNA deoxyribonucleic acid, IFALD intestinal
failure associated liver disease.
M.J. Johnson et al.
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Table 3. Key research priorities for venous access, complications, organizational aspects, home parenteral nutrition and ready to use and
standardized formulations in parenteral nutrition.
Topic (number of respondents) Priorities Number
of votes
Rank
Venous access (56) In children and infants who receive PN, explore the use of heparin or other
anticoagulant agents to prevent CVC occlusion or thrombosis, including
optimal doses and most effective mode of administration
26 1
In newborns and small children, determine the best landmarks for safe CVC
tip positioning
21 2
For all children and infants who receive PN, assess the efficacy of ultrasound
guidance in preventing complications
20 3
For all children and infants who receive PN, establish the most cost-effective
use of line locks in clinical practice to prevent occlusion and infection
19 4
In children and infants who receive PN, evaluate the most reliable dressing
methods for short-term catheters, and for a tunneled CVC
15 5
Complications (56) For pediatric patients on long-term PN, establish a more complete
understanding of the pathogenesis of IFALD
30 1
For all children and infants who receive PN, investigate the role of antibiotic,
antifungal, and ethanol locks in CVCs as an adjunct to systemic therapy or as
an alternative to line removal
21 2
In children who receive PN who have CRBSI, define the optimal duration of
therapy for treatment with or without catheter removal
19 3
Establishing more drug and PN brand specific data regarding the impact of
medications on PN stability. This also applies to interactions with specific
equipment and tubing and will vary depending on concentrations and
flow rates
18 4
For pediatric patients who receive long-term PN, further explore the use of
ursodeoxycholic acid for the prevention of PN-related cholestasis, including
data on liver disease and long-term outcomes
18 4
Organizational aspects (56) For all children and infants who receive PN, evaluate (ideally using RCTs) the
choice of enteral feed (e.g. elemental vs. polymeric vs. extensively hydrolyzed
formula) and feeding method (e.g. continuous vs. intermittent/bolus feeding)
while on PN in terms of their effect on tolerance and energy and nutrient
balance
28 1
For all children and infants who receive PN, develop a basic monitoring
protocol considered essential to ensure safety of patients receiving long-term
PN, together with follow-up and monitoring, together with a minimal data set
23 2
In all children and infants who receive PN, assessing the benefits of cycling PN
on short- and long-term outcomes, and the optimal regimens for doing this in
different patient groups
22 3
For all children and infants who receive PN, clearly describe the essential
elements of a PN ordering process aimed at minimizing the risk of errors
21 4
For all children and infants who receive PN, develop a non-invasive test for
small intestine bacterial overgrowth
21 4
Home parenteral nutrition (56) For all children and infants who receive home PN collecting long-term
outcome data, perhaps as part of an international database
20 1
Developing pediatric standard formulations for pediatric home PN,
particularly those that could be kept at room temperature
18 2
In children and infants who receive Home PN, carry out large multicentre
audits of new treatments for weaning PN, e.g. use of GLP-2 in long-term
patients at home, as this would help drive practice and the research agenda
16 3
In children and infants who receive Home PN, explore better strategies to
prevent IFALD and other hepatobiliary disease
16 3
For children and infants who receive Home PN, establish a network for
performing multicentre clinical trials of home PN
14 5
Understanding of the impact of home PN on quality of life of children and
their families
14 5
Ready to use and standardized
formulations (55)
For all children and infants who receive PN further evaluate the impact of
standardized PN compared to individually tailored PN, including costs and
outcomes
38 1
Developing enhanced informatics systems for the prescription,
administration, and assessment of PN in pediatric patients
26 2
For neonatal and pediatric patients who require PN, developing multi-
chamber PN bags, and assessing these in a formal trial
22 3
M.J. Johnson et al.
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differences and the impact of over- and undernutrition on
outcome, the optimal timing, dose, and composition of an amino
acid mixture for critically ill children remains unclear. Since high
doses appear harmful during the acute phase of critical illness,
further research in this area is urgently needed (see Table 1).
Lipids
Further well-designed and adequately powered studies are
necessary to determine the optimal and/or maximal dose of lipid
infusion and the long-term effects on morbidity, growth, and
neurodevelopment. In preterm infants, there is some evidence
that they have lower amounts of docosahexaenoic acid (DHA) and
arachidonic acid (AA) postnatally, which has been associated with
increased risk of morbidities such as retinopathy of prematurity
(ROP) and adverse neurodevelopmental outcome6. New lipid
emulsions specifically designed for preterm infants and containing
higher amounts of DHA and AA should be developed and tested.
The impact of different intravenous lipid emulsions (ILEs) on
inflammatory states, infection risk, and pulmonary hypertension is
not fully understood and more high-quality randomized con-
trolled trials (RCTs) are needed.
Several observational studies have reported the efficacy of pure
fish oil (FO) ILE as monotherapy in the treatment of IFALD in
infants and children, though from studies to date it is unclear
whether reversal of cholestasis was because of decreasing lipid
intake or the effect of FO itself (including the high α-tocopherol
load) or a combination of each. Definitive studies in this area,
particularly in relation to both the safety and efficacy of the long-
term use of FO, would be beneficial7.
Carbohydrate
The relationship between hyperglycemia and lipid metabolism is
not fully understood, particularly in preterm infants, and it is not
clear why some preterm infants are less able to tolerate
intravenous glucose while others can metabolize normal or even
higher intakes without adverse effects3. Data to help determine
whether insulin use or reduction in glucose intake, or a
combination of both, leads to the best short- and long-term
clinical outcomes in preterm infants are required (Table 1).
Similarly, there are limited data on the efficiency with which
glucose is utilized, together with endogenous glucose production
rates, for infants and children3.
Fluid and electrolytes
There are major gaps in knowledge regarding the pathophysio-
logical mechanisms underlying fluid balance and distribution in
critically ill children, particularly preterm and extremely low birth
weight (ELBW, <1000 g) and very low birth weight (VLBW, <1500
g) infants8 (Table 2). The movement of water between physical
compartments in the immediate postnatal period, is also not fully
understood9.
The impact of fluid therapy during the transition phase in the first
few days of life is not well described, and an understanding of the
fluid shifts during this period is vital to define the “optimal weight
loss” and consequent fluid and electrolyte intake strategy,
particularly in small for gestational age and ELBW infants10. Further
work determining the optimal electrolyte to macronutrient ratios in
PN for sodium, potassium, phosphorous, and other electrolytes is
also a priority. Clinical trials to establish optimal fluid and electrolyte
intake during mixed (parenteral and enteral) nutrition are also
warranted, and there is interest in studying the consequences on
the ratio of intracellular fluid and extracellular fluid (ECF), and its
composition under the current PN recommendations.
For children and infants beyond the neonatal period, the most
significant change relates to the use of isotonic fluid as an intrave-
nous fluid for “maintenance hydration” in sick children11–13,
especially during the first 24 h8. Fluid distribution is different
depending on the osmolarity of the solution being used, with
hypotonic solutions distributed in the intracellular compartment and
isotonic maintenance solutions mainly remaining in the extracellular
compartment14. The latter may imply a lower fluid requirement than
the volumes estimated by the traditionally used Holliday-Segar
formula8. An understanding of this relationship between fluid
distribution and fluid requirements is currently lacking.
Calcium, phosphate, and magnesium
There is currently no practical way of monitoring bone mineral
(microcrystalline apatite) accretion at the bedside, and no good
surrogate marker for monitoring bone mineral accretion. There-
fore, it is not currently clear what amounts and ratios of calcium,
phosphate and magnesium should be provided to ensure optimal
growth and bone mineralization in children, particularly in the
context of preterm infants and critically ill children. The optimal
phosphate intakes for both stability, and growth and bone
mineralization in the context of refeeding syndrome and critical
illness should also be more clearly defined by research evidence,
as should the optimal plasma phosphate concentration (Table 2).
Micronutrients
Micronutrients are an important component in any PN regimen in
children15, though iron is not routinely added to PN due to
stability issues. Different approaches for meeting iron require-
ments of children on long-term PN, including assessment of
stability of iron in different PN solutions and safety of different
doses and different iron compounds have not been well
investigated (Table 2). Studies which define requirements as well
as toxicity of iodine, copper, chromium, manganese, molybde-
num, and selenium at different developmental stages in relation
to health outcomes would help inform practice (Table 2).
Regarding vitamins, there has been a relative paucity of new
research and data in the past 30 years, and optimal doses and
infusion conditions in preterms, infants, and children have not
been established (Table 2). Current recommendations for vitamins
doses are largely based on expert opinion and there is a pressing
need for more research to establish these15, 16.
Venous access and complications
Some major clinically relevant gaps in current knowledge
regarding choice of appropriate central venous catheter (CVC),
selection of site, method of insertion, nursing care, handling and
hygiene remain, and represent priorities for future research
(Table 3). There is little evidence from clinical trials relating to
Table 3 continued
Topic (number of respondents) Priorities Number
of votes
Rank
Investigating whether each center is able to manufacture a composition of PN
for neonatal and pediatric patients requiring PN, that is compliant with the
current new recommendations, with consideration of the case for a
standardized European PN prescription
19 4
CVC central venous catheter, PN parenteral nutrition, CRBSI catheter-related bloodstream infection, RCT randomized controlled trial, GLP-2 glucagon like
peptide 2, IFALD intestinal failure associated liver disease.
M.J. Johnson et al.
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optimal CVC tip position in infants and children in order to
minimize risk of complications. Defining reliable radiological
landmarks to enable safe positioning of the CVC tip in infants
and children and determining the role of ultrasound guidance in
order to prevent complications are key areas of clinical uncertainty.
Diagnosis and management of catheter related sepsis, including
new methods and actions to implement measures to reduce
infection risk, are also an area of growing research interest17.
Studies comparing dressing methods are scarce and of poor
quality, leaving uncertainties regarding the most appropriate
dressing method (see Table 3).
Over 80% of venous thromboembolism in newborns and >40%
in older children are associated with CVC. Establishing effective
techniques for maintaining CVC patency and preventing throm-
bosis are the most clinically relevant knowledge gaps requiring
urgent studies.
Organizational aspects of parenteral nutrition
Cyclical PN (i.e. infusion for <24 h continuously) may have
physiological and psychological advantages for infants and
children, though current recommendations are largely based on
small studies that assessed physiological changes when cyclical
PN was introduced18, 19.
There is no standard biochemical monitoring regimen for PN,
and a minimum data set for stable patients at different ages
should be defined in order to avoid unnecessary and expensive
repeat testing. New ways of defining and assessing specific
complications, such as IFALD (including liver fibrosis), need to be
developed20, 21 and should include a non-invasive technique for
the measurement of hepatic venous pressure gradient22 and
further refinement of transient elastography23.
Small intestinal bacterial overgrowth is thought to contribute to
development of IFALD but is difficult to diagnose24. Polymerase
chain reaction (PCR) techniques using bacterial 16S ribosomal RNA
primers25 have potential to serve as a guide for antibacterial
therapy. A simple test for bacterial overgrowth is required to
inform the need for interventions and their effectiveness. Similarly,
there are limited data with regard to optimum feed type (in the
absence of breast milk) and mode of enteral nutrition (continuous
vs. bolus) for infants on PN26.
Home PN
There are still some gaps in knowledge and unanswered questions
in relation to the impact of Home PN (HPN) in terms of quality of
life, benefits, and costs (Table 3). There is little evidence regarding
optimal weaning strategies, and the potential for standardized
solutions suitable for HPN is relatively underexplored. There is
emerging evidence that the use of standardized home PN
solutions may be comparable to individualized solutions in terms
of maintaining growth and serum biochemistry, though larger
studies are needed to confirm this27. The use of strategies to
reduce complications such as infection and IFALD have not been
researched thoroughly in the context of HPN.
Ready-to-use standardized vs. individualized pediatric PN
preparations
Large multicentre RCTs, or at least observational cohort studies
based on large databases comparing the outcomes of infants
and children given individually tailored PN preparations to those
given standardized “ready-to use” PN solutions, would help to
establish evidence-based recommendations, and more importantly
specifically define the patients and conditions where individually
tailored or standardized ready-to-use PN preparations are advanta-
geous (Table 3). The other area in need for on-going research as
well as industrial development is the improvement and sophistica-
tion of ready-to-use all-in-one PN preparations, alongside
improved computer-based software to aid their prescription.
Overall priorities in pediatric PN
Of the 99 total research priorities identified by the original
ESPGHAN/ESPEN/ESPR/CSPEN guideline authors, 74 received at
least one vote. Six received 10 or more votes and so were
considered more important than others (these top six are shown in
Table 4). The most important research priority was to understand
the relationship between total energy intake, rapid catch-up growth,
later metabolic function and neurocognitive outcomes. Research
into the optimal intakes of macronutrients needed in order to
achieve optimal outcomes also featured prominently. For the
remainder, there were multiple topics that received totals of 9, 8,
7 votes, meaning that these top six were clearly the highest priority.
DISCUSSION
This international expert consultation highlighted 99 research
priorities in the field of pediatric PN. This consultation was
intended to define the most urgent research studies needed to
determine effective strategies in quality improvement and patient
safety. To achieve this goal, we established the six most important
research priorities from all topic areas based on each respondent’s
top five priorities.
The most important research priority identified was gaining an
understanding of the relationship between total energy intake,
the potential adverse effects of rapid catch-up growth on later
metabolic function and potential neurocognitive benefit for all
age groups. Research into the range of intakes of macronutrients
needed in order to achieve optimal outcomes also featured
prominently, and in particular the ratio of energy to protein and
the optimal dose and composition of amino acid mixture for
Table 4. Overall highest research priorities in pediatric parenteral nutrition.
Research priority Number of votes Rank
For all children and infants who receive parenteral nutrition, understand the relationship between total energy intake,
rapid catch-up growth and long-term metabolic function and neurocognitive outcomes
23 1
In critically ill children, define optimal energy intake for different phases of illness (acute, stable, and recovery) and the
optimal route and doses of macro- and micronutrients
16 2
For preterm infants, establish a robust definition of hyperglycemia, and compare to effectiveness of management
using insulin to a reduction carbohydrate for its impact on mortality, morbidity, growth, and long-term metabolic
function and neurocognitive outcomes
14 3
In preterm infants, determine the initial, optimal, and/or maximal dose of lipid infusion and the ideal fatty acid
composition needed to achieve the best long-term effects on morbidity, growth, and neurodevelopment
13 4
In preterm infants, define optimal energy:protein ratio for growth and later long-term metabolic function and
neurocognitive outcomes
12 5
For critically ill children, define the optimal dose and composition of amino acid mixture for optimal short- and long-
term clinical outcomes
10 6
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optimal short- and long-term clinical outcomes. The latter is of
interest as, despite the fact that inadequate protein balance and
poor growth have been associated with currently available
commercial mixtures of essential amino acids28 and conditionally
essential amino acids29, there is little current research into
modifying current commercial mixtures to try and improve
outcomes, due to the complexity and expense this would involve.
Of the 99 priorities identified, 15 of these related specifically to
preterm infants, which means they are perhaps slightly over-
represented compared to other groups. Most of the research
needs for preterm infants related to understanding basic nutrient
requirements and their impact on long-term outcomes, particu-
larly neurodevelopment.
An overarching theme across all nutrients, but macronutrients
in particular, was that research into the intake required in order to
achieve optimal outcomes was needed. This is a broad and
challenging task. How to define and measure optimal outcomes
remains a challenge in many areas of medicine, but especially so
in pediatrics, given that long-term outcomes also involve optimal
neurological, cognitive, and functional development and the
impact of nutrition and growth in early life on the risk of non-
communicable diseases such as coronary heart disease and
metabolic syndrome in adulthood. Defining which outcomes are
important to clinicians, patients, families, and other stakeholders is
essential, and central to this is the work of the Core Outcome
Measures in Effectiveness Trials (COMET) initiative30. Given the
relatively small numbers of patients who receive PN, the use of
registries and national databases is also needed to improve our
understanding of practice and outcomes in this area. Such
systems could also be used to drive larger trials using newer
methodologies such as randomized point-of-care trials or registry
trials as an alternative to conventional RCTs.
A limitation of the work described by this paper is that the
authors and survey respondents came primarily from European
countries, with some from China and Israel. The results of this
work therefore reflect the priorities of those countries and are not
a truly global international consensus. Furthermore, the guideline
authorship group was drawn from the members of the contribut-
ing societies by volunteers and nominations, and so may reflect
the priorities of those individuals to some extent, so may not be
fully representative of the groups surveyed. In addition, families or
patient groups drawn from those who require PN in infancy and
childhood were not included. Furthermore, another potential
limitation of the current approach to ranking is that it was a simple
vote-based process. The intention of the paper was to collate all
the research gaps that were identified as part of the process of
researching and writing the 2018 ESPGHAN/ESPEN/ESPR/CSPEN
guidelines. Given that each topic area had generated multiple
research gaps, we chose to use a ranking system to help readers
understand the ones the guideline authors felt were most
pressing. We chose to list the top six overall priorities here, as
these were the only ones that received 10 or more votes and were
clear separated from the others as frontrunners. For the
remainder, there were multiple topics (74) that received similar,
non-unique, numbers of votes, meaning it is difficult to genuinely
say that any one of these priorities is particularly more important
than the other. An additional potential concern is that the
priorities identified may reflect the authors own research interests,
rather than specific needs, though the fact that a broad range of
priorities across all areas have been identified, including the top
six, suggests this was ultimately not an issue.
The list of research priorities presented here suggests there is still
much to do. However, much progress has been made in the past
few decades and pediatric PN is now safe, effective, and a vital tool
in the support of children who cannot be fed enterally. Future
research seems to need to focus on optimizing the composition and
administration of PN such that it confers maximal benefit. By listing
and highlighting research priorities in this area, this paper acts as a
focus point to galvanize the pediatric nutrition research community
towards addressing these issues on a grand scale. By making
substantial progress in these areas over the next years, we believe
that we may promote the future health and well-being of preterm
infants, neonates, or older children in need of PN.
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